Roche
9115 Hague Road
Indianapolis
Indiana
46256
United States
Tel: 317-521-2000
Fax: 317-521-2090
Website: http://www.roche.com/
About Roche
Founded in 1896, Roche is a global pioneer in pharmaceuticals and diagnostics and is the world’s largest biotech company, focused on advancing science to improve people’s lives. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics. The Diagnostics division develops and produces medical tests that provide information to help healthcare professionals find the right treatment for patients and deliver the best patient care to improve, prolong and save lives.
We offer a wide range of research and in vitro (outside the body) diagnostic tools that help in the early detection, prevention, diagnosis and treatment of diseases like congestive heart failure, HIV, hepatitis and diabetes, as well as medical conditions like fertility and blood coagulation. These products and services are used by researchers, physicians, patients, healthcare facilities and laboratories around the world.
Roche Diagnostics has its North American headquarters in Indianapolis. The Roche campus, located at 96th Street and Hague Road, spans about 155 acres and is home to U.S. research and development, laboratory, manufacturing, distribution, IT and administrative operations. The campus supports six diagnostics business areas: Diabetes Care, Centralized Diagnostics, Sequencing and Life Science, Molecular Diagnostics, Point of Care Diagnostics and Tissue Diagnostics. About 4,000 employees report into Indianapolis, with about 2,900 working onsite.
Roche Molecular Solutions, one of the global business areas within Roche Diagnostics, brings together the diagnostic power of molecular, tissue and sequencing technologies.
With the goal of revolutionizing diagnostic decisions through integrated solutions, Roche Molecular Solutions brings together the latest technologies withinmolecular diagnostics (polymerase chain reaction or PCR-based testing), tissue diagnostics (tissue biopsy testing) and sequencing solutions (next-generation DNA and RNA sequence-based testing) to advance the standard of care for everyone.
California Location:
4300 Hacienda Drive
Pleasanton, California 94588
United States
Tel: 925-730-8000
Fax: 925-225-0479
1879 articles with Roche
-
Inflazome Announces Acquisition by Roche
9/21/2020
Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases
-
Swiss pharma giant Roche acquired Ireland’s Inflazome and its NLRP3 inflammasome inhibitors aimed at multiple inflammatory diseases for €380 million (about $451 million) in an upfront payment.
-
Roche launched its Elecsys Anti-SARS-CoV-2 S antibody test for markets that accept the CE Mark.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
-
As we head into cold and flu season, the question arises: Can you get COVID-19 and the flu at the same time?
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.
-
This test will give healthcare providers a single result to confirm an HIV diagnosis with patients and differentiate between HIV-1 and HIV-2.
-
August has been a busy month for the U.S. Food and Drug Administration. The final two weeks are marked by a number of PDUFA dates, although a few of those drugs have already been approved.
-
Regeneron and Roche Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Cocktail for COVID-19
8/19/2020
REGN-COV2 is Regeneron's two-antibody 'cocktail' currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection
-
Regeneron will distribute REGN-COV-2 in the U.S. and Roche will handle distribution outside the U.S.
-
Celleron Therapeutics signed a licensing agreement with Roche for the worldwide rights to cancer drug emactuzumab, a monoclonal antibody directed against colony-stimulating factor 1 (CSF-1R) expressed on macrophages.
-
Roche launches cobas prime Pre-analytical System, a first-of-its-kind solution designed to automate all common manual steps in molecular diagnostics laboratories
7/30/2020
Roche is first company to offer molecular labs complete end-to-end automation solution for testing consolidation
-
Roche’s Actemra failed to meet its primary and secondary endpoints in a late-stage study involving hospitalized patients with severe COVID-19 associated pneumonia.
-
Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism to Treat Immune-Mediated and Neurological Diseases
7/21/2020
Jnana to receive $40 million upfront and is eligible to receive milestone payments with potential for future payments exceeding $1 billion
-
PicnicHealth Announces Strategic Partnership with Roche to Generate Scientific Insights from Real World Data
7/16/2020
Real-world Datasets Will Be Used to Advance Research in Multiple Therapeutic Areas across Neurology, Hematology, and Rare Disease
-
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
7/14/2020
Blueprint Medicines and Genentech, a member of the Roche Group, to co-commercialize pralsetinib and equally share profits in the U.S.
-
Roche, Summit Cancer Centers to collaborate on use of new digital healthcare tools to enable more personalized cancer care
7/13/2020
Initiative will include first integration of NAVIFY Tumor Board software with OncoEMR system to incorporate electronic medical record information in tumor board reviews
-
Reverie Labs Enters Multi-target Collaboration Agreement with Roche
7/8/2020
Reverie Labs , a pharmaceutical company pioneering the application of artificial intelligence in the discovery and development of next-generation kinase inhibitors, today announced a multi-target collab
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
-
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer
7/2/2020
Clinical collaboration marks an important milestone in partnership with Exelixis to further develop cabozantinib